modelL03AB07

Diagram of L03AB07

Extends from Pharmacokinetic.Models.PK_2C.

Information

name:InterferonBeta1a
ATC code:L03AB07
route:intramuscular
compartments:2
dosage:30mg
volume of distribution:0.25L
clearance:0.124L/h/kg
other parameters in model implementation

Interferon beta-1a is a recombinant form of human interferon beta, used primarily in the treatment of relapsing forms of multiple sclerosis (MS). It is approved by regulatory agencies such as the FDA and EMA for MS to reduce frequency of relapses and slow progression of physical disability.

Pharmacokinetics

Pharmacokinetics reported for healthy volunteers and MS patients after single subcutaneous or intramuscular administration.

References

  1. David, OJ, et al., & Schmouder, RL (2012). Clinical pharmacokinetics of fingolimod. Clinical pharmacokinetics 51(1) 15–28. DOI:10.2165/11596550-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22149256

  2. Saida, T, et al., & Hao, Q (2012). Intramuscular interferon beta-1a is effective in Japanese patients with relapsing-remitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhanced MRI brain lesions. Multiple sclerosis (Houndmills, Basingstoke, England) 18(12) 1782–1790. DOI:10.1177/1352458512442261 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22492130

  3. Rogge, MC, et al., & Galluppi, GR (2014). Interferon beta assessment in non-Chinese and Chinese subjects: pharmacokinetics and pharmacodynamic activity of an endogenous cytokine are not race dependent. Journal of clinical pharmacology 54(10) 1153–1161. DOI:10.1002/jcph.311 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24737408

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)